Introduction
Genetic immunization strategies have become attractive for the development of melanoma vaccines, because a number of antigens recognized by cellular components of the immune system have been identified at the molecular level in melanoma patients. 1 These melanoma antigens include normal cellular proteins, such as tyrosinase-related protein 2 (TRP-2) involved in melanin synthesis, which are constitutively expressed in melanocyte and melanoma cells. 2 Previous reports showed poor immunogenicity of conventional plasmids encoding nonmutated autologous melanocyte/melanoma antigens. [3] [4] [5] Furthermore, genetic immunization of C57BL/6 (B6) mice with cDNA encoding autologous murine melanocyte/melanoma protein, such as murine TRP-2 (mTRP-2), failed to break peripheral T-cell tolerance to self-antigens. 6 Subsequently, some investigators have attempted to break the tolerance using genes encoding heterologous melanocytic antigens such as human TRP-2 or chimeric genes encoding green fluorescent protein (GFP) fused to TRP-2. 5, 7 Clinical application of these systems, however, can result in certain predictable side effects or risks, especially after repeated vaccinations. For example, neutralizing antibodies for heterologous gene products or peptides may interfere with the vaccination effect. Furthermore, anaphylactic shock caused by homocytotropic antibodies or systemic inflammation mediated by CD4 + T cells specific for those heterologous gene products/peptides may occur.
Autoreactive T cells are not completely deleted within the thymus, but such T cells become tolerant to selfantigens in peripheral lymphoid tissues. 8 Self-tolerance is broken in certain conditions. One case is that selfantigens are effectively presented by professional antigen-presenting cells (APC) or dendritic cells (DC) to those tolerant T cells. 9 Furthermore, some cytokines such as interleukin 12 (IL-12) break the peripheral tolerance of CD8 + T cells specific for autologous tumor antigen, probably through activation of DC, 10, 11 although IL-12 is not always suitable for clinical trials presently due to its side effects.
Antigen presentation to CD8 + T cells is mediated by MHC class I molecule expressed on cells. Primarily, CD8 + T cells recognize MHC class I-associated peptides derived from endogenous antigens, such as oncogene products or viral antigens, located in the cytosol. Prior to antigen presentation by MHC class I molecules, antigens must be ubiquitinated and then processed to antigenic peptides by the proteasome. [12] [13] [14] Immunization with DNA vaccine containing ubiquitin gene fused with minigenes encoding cytotoxic T lymphocyte (CTL) epitopes of melanoma differentiation antigens broke self-tolerance for the tumor antigen through effective antigen processing and presentation. 15 Here, we constructed a chimeric DNA encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2, designated pUB-TRP-2, and then immunized B6 mice using a gene gun containing the chimeric naked DNA, before or after inoculation of B16 melanoma cells obtained from B6 mice. This strategy is based on the rapid destruction of cellular proteins through the UFD (UB fusion degradation) pathway, a virtual route of the ubiquitin-proteasome system. 16 By using this DNA vaccine technique, we succeeded in inducing antitumor immunity mediated by CD8 + T cells in the host mice. Intriguingly, the antitumor immunity induced by this DNA immunization was almost completely cancelled in mice deficient in the proteasome activator PA28a/b. 17 Taken together, our results indicate that ubiquitin fused to mTRP-2 plays an essential role in introducing mTRP-2 protein into the proteasome-dependent degradation and creating epitopes presented by MHC class I, resulting in the preferential activation of mTRP-2-specific CD8 + T cells.
Results

Rapid degradation of ubiquitin-fused TRP-2 by the proteasome
Most endogenously synthesized peptides such as mutant and viral antigens are processed by a cytosolic protease, the proteasome, followed by ubiquitination of those antigens, and then presentation to MHC class I molecules, resulting in activation of corresponding CD8 + T cells. [12] [13] [14] Accordingly, artificially ubiquitinated mTRP-2 should be directed to the proteasome and effectively presented to MHC class I molecules. To confirm this scenario, we prepared the expression vectors of pTRP-2 encoding the full-length TPR-2 protein tagged with HA epitope at its C-terminus (TRP-2-HA) and pUB-TRP-2 encoding modified ubiquitin (G76A) in-frame with TRP-2-HA so as not to be cleaved by ubiquitin C-terminal hydrolases in cells (Figure 1a ). To analyze expression of TRP-2 and its degradation by proteasomes, COS-7 cells were transfected with pTRP-2 or pUB-TRP-2 in the presence or absence of a proteasome inhibitor, MG-132 (Figure 1b) . The expression of the UB-TRP-2 fusion protein was considerably lower than that of TRP-2 alone in the absence of MG-132. When the transfected cells were treated with MG-132, however, the level of UB-TRP-2 recovered to the same level as that in TRP-2. To further confirm, pulse-chase experiments were performed ( Figure 1c) . In COS-7 transfected with pTRP-2, TRP-2 was detected up to 20 min irrespective of the existence of MG-132. In contrast, in those transfected with pUB-TRP-2, TRP-2 was completely degraded within 20 min. Addition of MG-132 showed prolonged detection of the fusion protein. These results suggest that ubiquitin-fused TRP-2 protein is unstable compared to unfused TRP-2 and is rapidly degraded by the proteasome.
Antitumor immunity against B16 melanoma CTL epitopes including mTRP-2 181-188 are generated by the ubiquitin-proteasome pathway. 17 Therefore, we expected that antigen presentation of MHC class Iassociated TRP-2 peptides to CD8 + T cells becomes significantly effective following vaccination with the ubiquitin-fused TRP-2. C57BL/6 mice were immunized with pTRP-2 or pUB-TRP-2 three times at 1-week intervals using a gene gun and a total dose of 18 mg plasmid per mouse. A week after the last immunization, mice were challenged subcutaneously with 2 Â 10 5 B16F1 cells. Control mice and mice immunized with pTRP-2 showed rapid tumor growth, whereas 85% of mice immunized with pUB-TRP-2 were free of tumors and the remaining 15% of the mice exhibited almost complete suppression of tumor growth (Figure 2a) . Strictly, all mice immunized with pUB-TRP-2 survived over 80 days after implantation of tumor cells, although all mice of the other two groups died within 60 days (Figure 2b) . Furthermore, immunization with pUB-TRP-2 was also effective in suppressing the growth of B16F10 melanoma cells, a more virulent type of melanoma (Figure 2c) . A total of 43% of mice immunized with pUB-TRP-2 survived over 45 days after implantation with B16F10 tumor cells, whereas all mice of the other two groups were dead within 35 days (Figure 2d ). The number of lung metastatic tumors with B16F10 cells was significantly lower in pUB-TRP-2-immunized mice than in control or pTRP-2-immunized mice (Figure 2e ). On the other hand, immunization with pUB-TRP-2 in B6 mice did not affect tumor formation of 3LL lung carcinoma cells, which do not express TRP-2 antigens (Figure 2f ), indicating that the antitumor immunity acquired by pUB-TRP-2 vaccine is a specific event for melanoma cells. These results show that forced expression of ubiquitin-fused TRP-2 proteins in vivo induces antitumor immunity against B16 melanoma more effectively than that of native TRP-2 proteins, as evaluated by tumor growth, survival rate and lung metastasis.
Effector cells in the pUB-TRP-2 induce antitumor immunity
We speculated that immunization with pUB-TRP-2 preferentially activated antigen-specific CD8 + T cells through efficient antigen processing of the encoded protein by the proteasome. To determine the effector cells in the observed protective immunity, we treated pUB-TRP-2-immunized mice with anti-CD4 or anti-CD8 antibody to deplete the corresponding T-cell subset, and then the mice were implanted with B16F1 cells. As expected, anti-CD8 treatment completely abolished the antitumor immunity induced by pUB-TRP-2 immunization ( Figure 3 ). In contrast, treatment with control IgG, anti-CD4 antibody, did not attenuate the tumor growth. The crucial role of CD8 + T cells was confirmed also by intracellular IFN-g staining assay (Figure 4a ). These T cells had the potential to generate IFN-g but CD4 + T cells did not. These results indicated that the antitumor immunity provoked by pUB-TRP-2 immunization is mediated by tumor-specific CD8 + T cells that recognize the TRP-2 epitope presented on MHC class I molecules. To confirm the existence of antigen-specific CD8 T cells, lymph node cells obtained from vaccinated mice were stained with the tetramer of MHC class I molecule and dominant CTL epitope TRP-2 181-188 . Antigen-specific CD8 T cells significantly increased in mice vaccinated with pUB-TRP-2 but not with pTRP-2 ( Figure 4b ). In order to clarify the role of the proteasome in antitumor immunity induced by pUB-TRP-2, we used PA28ab
mice, because TRP-2 181-188 , one of the major antigenic peptides, is generated by the proteasome activated by PA28. 17 There was no significant difference in tumor growth between PA28ab À/À mice and wild-type mice after subcutaneous challenge with B16F10 ( Figure 5a ). Immunization of wild-type mice with pUB-TRP-2, again, suppressed tumor growth. In contrast, PA28ab
À/À mice immunized with pUB-TRP-2 were markedly susceptible to B16F10 tumor challenge compared with wild-type B6 mice immunized with the same plasmid ( Figure 5a ). And the level of tumor growth in PA28ab
À/À mice immunized with pUb-TRP-2 was comparable to that in PA28ab
mice immunized with pTPR-2 ( Figure 5a ). Coincident with the result of tumor growth, CTL activity against TRP-2 181-188 epitope was lower in PA28ab À/À mice immunized with pUB-TRP-2 than in wild-type mice ( Figure 5b ). These results prove that the proteasome activated by PA28 plays an important role in the induction of mTRP-2-specific CTL and antitumor immunity following DNA vaccination with pUB-TRP-2. It should be noted that PA28ab À/À mice are not always immunocompromised hosts even in the level of CD8 + T cells as well as CD4 + T cells. When these deficient mice have been immunized with plasmid DNA encoding GFP by the gene gun, similar levels of antigen-specific IgG are produced in these mice compared with those in 35 S-labeled-amino acids for 30 min 18 h after transfection. Labeled cells were washed and chased for the indicated period, and then they were harvested. Some cells were treated with 10 mM of MG-132 when they were labeled and chased. An immunoprecipitation analysis was performed with anti-HA monoclonal antibody, and the precipitants were separated with SDS-PAGE.
DNA vaccine against melanoma M Zhang et al wild-type mice, indicating that CD4 + T cells are intact in those mice. 17 Further, we confirmed that these mice develop the potential to mount MHC class I-restricted CD8 + T cells specific for OVA and influenza antigens. 18 Therapeutic effect for melanoma by immunization with the plasmid DNAs
From the point of view of clinical application, it is more important to examine the therapeutic effects of this DNA vaccination method against melanoma implanted before vaccination. To test this effect, B6 mice were implanted with B16F1 melanoma cells before vaccination (day 0). Treatment with pTRP-2, pUB-TRP-2 or mock plasmid commenced on day 1 and was then repeated twice a week in the following 2 weeks. As shown in Figure 6 , immunization of mice with pUB-TRP-2 resulted in marked suppression of tumor growth compared with mice immunized with mock or pTRP-2 plasmid. These results strongly indicate that immunization with DNA plasmid is effective even after development of the tumor, thus confirming of its potential clinical effectiveness against melanomas.
Discussion
Several melanoma antigens capable of activating immune responses have been defined. 19, 20 Among them, the melanocyte lineage differentiation antigens (MDAs) are most prominent in the induction of immune responses. TRP-2 is one of the MDAs expressed in both normal and malignant melanocytes in humans and mice.
2,21 CTLs play a major role in antitumor immunity. 22 Several epitopes recognized by human CD8 + T cells are included in the TRP-2 protein. 23 Bloom et al 21 identified a major murine CTL epitope, TRP-2 181-188 , presented on the 
H-2K
b MHC class I molecule, and reported that passive transfer of TRP-2 181-188 -specific CTLs into C57BL/6 (B6) mice had a therapeutic effect against established B16 lung metastasis. Although TRP-2 is a self-antigen, a significant number of CTL precursors potentially reactive to TRP-2 evade intrathymic selection. However, it is generally accepted that T cells specific for autologous murine melanocyte proteins such as TRP-2 fall into tolerance in the peripheral lymphoid system. Accordingly, immunization with this autologous antigen including genetic immunization could not break peripheral T-cell tolerance to the self-antigens, and thus failed to provide protective immunity against B16 melanoma cells. [3] [4] [5] [6] Overcoming these tolerance limitations is crucial to the development of effective immunotherapy for melanoma.
It is well established that 8-to 9-mer of antigenic peptides must be presented on MHC class I molecules of target cells to be recognized by specific CTLs. The proteasome is responsible for the proteolysis of intracellular proteins including tumor antigens to generate MHC class I ligands. [24] [25] [26] Prior to degradation by the proteasome, polyubiquitin chains should be covalently attached to the substrates by a multienzymatic system. 27 Interestingly, it has been shown that fusion of a viral protein with the ubiquitin moiety at its N-terminus facilitates the formation of CTL epitopes, resulting in immunity against viral infection. 28 It is notable that proteins fused with ubiquitin whose C-terminal glycine residue is replaced with another amino acid, so as not to be cleaved and removed by the cytosolic ubiquitin C-terminal hydrolase, are degraded more rapidly than nonfused proteins in a ubiquitin-proteasome systemdependent manner. This system is particularly called the UFD pathway. 16 Thus, fusion of ubiquitin to the protein requiring degradation by the proteasome seems to be a useful strategy to effectively create CTL epitopes.
In the case of melanoma, the biggest problem that has hampered successful immunization is that the tumor rejection antigen is a self-antigen. We assumed that tolerance against self-antigen might be broken by increasing the amount of presented epitopes. For this purpose, we applied artificially potentiated UFD pathway, constructing a naked DNA encoding a 'nonremovable' fusion protein between ubiquitin and the full-length mTRP-2. As expected, ubiquitin-fused TRP-2 proteins converted into an excellent substrate for the ubiquitin-proteasome pathway (Figure 1b) . Further, potent antitumor immunity was evoked against both low-virulent B16F1 and high-virulent B16F10 melanoma cells, as estimated by suppression of tumor growth, survival rate and lung metastasis (Figure 2 ). The depletion of CD8 + T cells ( Figure 3 ) and deficiency of the proteasome activator PA28ab (Figure 5 ), which is a prerequisite for proteasome-dependent processing of the major TPR-2 epitope, TRP-2 [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] , 18 counteracted the effect of vaccination. Thus, this protective immunity can be attributed to induction of melanoma-specific CTL Several investigators have approached to break peripheral T-cell tolerance using genes encoding heterologous melanocytic antigens such as human TRP-2 or chimeric genes encoding fused proteins between murine TRP-2 and foreign proteins like GFP. In this type of genetic immunization, CD4 + T cells recognizing those kinds of heterologous/foreign antigens are activated and then break peripheral tolerance of CD8 + T cells. In the present study, however, CD4 + T cells appeared not to be required. It is important to elucidate how CD8 + T cells are activated without support from CD4 + T cells in our system, although there are some reports that some professional DC directly activate CD8 + T cells without the support of CD4 + T cells. 7, 9 Further, Leitner et al recently reported that naked DNA vaccine encoding alphavirus replicon and mTRP-1 provides immunity to B16 melanoma. In this system, CD8 + T cells are also final effector cells and CD4 + T cells are not required, although they do not focus on 'ubiquitin-proteasome pathway', and speculate that such CD8 + T cells are induced through activating innate antiviral pathways such as TLR3. 29 There exist many reports that C57BL/6 mice show prominent vitiligo when mice have acquired antimelanoma immunity according to immunization with heterologous melanoma antigens/DNAs such as human TRP-2 and gp100. 30, 31 Strangely, however, vitiligo was scarcely seen in the present study, in which mice were immunized with DNA encoding a fusion protein between murine ubiquitin and murine TRP-2. The difference between our observation and theirs may be the difference in contribution of CD4 + T cells. In their system, CD4 + T cells as well as CD8 + T cells are required, while CD4 + T cells were not required in the present system. One possibility is that vitiligo is caused by nonspecific inflammation induced by those activated CD4 + T cells. It is worth noting that our previous finding should be documented. That is, we observed that C57BL/6 mice immunized with DNA encoding a fusion protein between GFP and murine TRP-2 also acquired a potent antimelanoma immunity mediated by CD4 + T cells as well as CD8 + T cells. These mice showed remarkable vitiligo (manuscript submitted). Antimelanoma immunity may not always correlate with vitiligo as reported by Bronte et al.
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Melanoma is one of the most common cancers and is the most serious type of skin cancer. In this study, we explored the potential of this DNA vaccine for melanoma treatment and demonstrated that this strategy was useful even after implantation of the melanoma cells in mice ( Figure 6 ). We propose here that genetic immunization with naked chimeric DNA encoding a fusion protein between full-length human TRP-2 and human ubiquitin is one of the possible strategies for clinical trial aimed at inducing potent protective immunity in melanoma Immunization with full-length autologous TRP-2 could offer many advantages over ordinary vaccine strategies using 8-to 9-mer peptides such as human TRP-2 181-188 . First, the ubiquitin-fused self-antigen(s) are rapidly degraded by the ubiquitin-proteasome pathway, resulting in efficient production of a variety of peptides including many CTL epitopes that might be presented by many types of MHC class I molecules. In other words, this type of vaccination would be available for patients with various types of MHC class I molecules. Second, the incidence of side effects should be low compared with vaccines that use vector viruses or heterologous peptides/genes. The latter types of vaccines could trigger certain side effects such as neutralizing antibodies, anaphylaxis mediated by homocytotropic antibodies and systemic inflammatory diseases mediated by CD4 
Materials and methods
Animals and tumors
We performed mouse studies in accordance with the institutional guidelines of Kyushu University. Female C57BL/6 mice (8 weeks of age) were purchased from SLC (Hamamatsu, Japan). Proteasome activator, PA28, knockout (PA28ab
) mice of C57BL/6 background were established by our group.
18 B16F1 and B16F10, murine melanoma cell lines, were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100 mg/streptomycin, 20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid, 50 mM NaHCO 3 and 2 mM L-glutamine. Lung carcinoma 3LL cell line derived from B6 mice was used as the control tumor.
Plasmid construction
Plasmid encoding mTRP-2 was constructed as follows: total RNA was separated from B16F1 cells and reversetranscribed to cDNA. TRP-2 cDNA was then amplified by PCR using sense 5 0 -GAATCCAAGCGGCCGCCAATT AAGAAGGCATGGGCCTTG-3 0 and antisense 5 0 -CCAT GGATCCTATTAGAGGCTAGCGTAATCCGGAACATCG TATGGGTAGGCTTCCTCCGTGTATCTCTTGCT-3 0 primers. PCR product of TRP-2 cDNA was inserted into NotI and BamHI site of pcDNA 3.1 (À) vector (Invitrogen, San Diego, CA, USA). Gene encoding mutant ubiquitin, whose C-terminal Gly residue was replaced by Ala (G76A), was amplified by PCR from genomic DNA obtained from the liver of BALB/c mice and was inserted into EcoRI and BamHI site of pcDNA 3.1 (À). Gene encoding TRP-2 was amplified again by PCR using sense 5 0 -TAGGATCCGGCCTTGTGGGATGGGGGCTT CT-3 0 and the same antisense primers. The mutant ubiquitin cDNA was then ligated to the 5 0 of the gene encoding TRP-2-in-frame and inserted into BamHI site of pcDNA 3.1 (À).
In vivo gene transfer and implantation of melanoma cells
We used a Helios Gene Gun (BioRad, NY, USA), as described previously. 11, 33, 34 Briefly, plasmid DNA was precipitated onto 1.6 mm gold particles and coated onto the inner surface of the tubing by a tube loader. The final tubing segment resulted in delivery of 0.125 mg gold particles and 2 mg plasmid DNA per transfection. pTRP-2, pUB-TRP-2 or pcDNA was transferred to three different portions of shaved abdominal skin three times at 1-week intervals. A total of 18 mg plasmid was administered into each mouse. At 1 week after the last vaccination, 2 Â 10 5 melanoma cells in 0.1 ml of PBS were implanted subcutaneously into the center of the abdomen of B6 mice. Tumor size was measured twice a week using a caliper and was calculated as p/6 Â {(a Â b) 1/2 } 3 , where a and b are two perpendicular major diameters of the tumor. 35 For the experiment of lung metastasis, B6 mice were intravenously challenged with 2 Â 10 5 B16F10 cells in 0.2 ml of PBS. At 2 weeks after the challenge, mice were killed, all lobes of both lungs were dissected out and metastatic tumors were counted. For the above experiments, each group consisted of six mice. For therapeutic trials, 5 Â 10 4 B16F1 cells in 0.1 ml of PBS were implanted subcutaneously in the abdominal area of B6 mice on day 0. pTRP-2, pUb-TRP-2 or pcDNA was transfected into three different portions of shaved abdominal skin three times, one of which was the tumor-implanted site. Treatment commenced on day 1 and was applied twice a week for 2 weeks (total five times). Each group consisted of eight mice. A total of 18 mg plasmid was administered into each mouse for one treatment.
In vitro transfection, Western blotting and pulse-chase analyses
A total of 500 000 of COS-7 cells in a 2.5 cm dish (Nunc, Roskilde, Denmark) were transfected with 2 mg pTRP-2 by using Lipofectamine (Invitrogen). At 24 h after transfection, cell lysates were prepared by adding 200 ml of lysis buffer (50 mM Tris-HCl, 1% nonidet P-40/1% sodium dodecyl sulfate (SDS), 1 mM leupeptin/ 100 mM phenylmethylsulfonylfluoride, 1 mM pepstatin A and 100 mM ethylenediamine tetraacetic acid). In some experiments, a specific inhibitor of proteasomes, MG132, was used at a concentration of 10 mM. A 10 mg portion of protein was used for Western blot with anti-HA antibody (mouse monoclonal antibody clone 12CA5, Roche, Mannheim, Germany) as the first antibody. Peroxidaseconjugated anti-mouse immunoglobulin G (IgG) (H+L) (Zymed Laboratories, San Francisco, CA, USA) was used as the second antibody. Binding antibody was detected by using enhanced chemiluminescence (ECL) reagents (Amersham Life Science, Buckinghamshire, UK). Some transfectants were labeled with 35 S-labeled-amino acids (0.12 mCi/ml) for 60 min 18 h after transfection (pulse). Cells were washed and harvested after incubation for up to 40 min (chase). Then, cells were lysed, and the protein extracts were adsorbed with protein G-agarose beads for 2 h followed by immunoprecipitation with 1 ml of anti-HA and 20 ml of the beads overnight. Beads were washed four times and suspended with SDS-PAGE sample buffer. A 15 ml portion of the supernatant was separated on SDS-PAGE under nonreducing conditions. Gels were DNA vaccine against melanoma M Zhang et al soaked in Amplify Fluorographic Reagent (Amersham) for 30 min, dried and exposed to photographic film.
Cytotoxicity assay
Mice were killed at the time of tumor challenge and their spleen cells (4 Â 10 7 ) were cocultured with mTRP-2 181-188 peptide (4 mg/ml) in six-well culture plates in complete RPMI 1640 medium. After 5-day culture, graded numbers of viable effector cells and [ 3 H]thymidine-labeled EL-4 cells (10 4 ) pulsed with mTRP-2 181-188 peptide (4 mg/ ml) for 2 h were placed into round-bottomed 96-well plates. After 4.5 h incubation, the media were harvested onto glass-fiber filters and radioactivity was counted using a b scintillation counter, and specific killing was calculated as described previously. 36 In vivo depletion of T-cell subsets Anti-CD4 mAb (clone GK1.5) or anti-CD8 mAb (clone 53-6.72) was injected intraperitoneally at 0.5 mg/mouse on days À3, À1, 1 and 3 of tumor challenge. Tumor cells were inoculated on day 0. Depletion of each T-cell subset was confirmed by flow cytometry; over 98% of the appropriate cell subset was depleted.
Detection of intracelluar IFN-g or antigen-specific CD8 + T cells by flow cytometry
One million splenocytes were cultured in RPMI 1640 complete medium with phorbol 12-myristate 13-acetate (50 ng/ml), calcium ionophore (1 mg/ml) and brefeldin A (1 mg/ml) for 4 h in a 12-well plate, then harvested and washed once with staining buffer. After centrifugation, cells were stained with allophycocyanin-labeled anti-CD4 antibody (clone GK1.5, BD Pharmingen) and PE-labeled anti-CD8 antibody (clone 53-6.72, BD Pharmingen) at 41C for 30 min and then washed with staining buffer. Cell pellets were fixed with 100 ml of 4% paraformaldehyde at 41C for 20 min. After washing, cells were stained again with FITC-labeled anti-IFN-g antibody (clone XMG1.2, BD Pharmingen), which was diluted in permeabilization buffer (1% heat-inactivated FCS, 0.1% sodium azide, 0.1% saponin in PBS) at 41C. To detect antigen-specific CD8 + T cells, lymph node cells were stained with FITC-CD8 antibody and PE-conjugated H-2K b -TRP-2 181-188 tetramers (Proimmune, Springfield, VA, USA). After washing twice, cells were collected on a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA), and data were analyzed using CellQuest version 3.1 software (BD Biosciences).
